Education
About Us
Working with TipRanks
Follow Us
Imagion Biosystems Ltd. (AU:IBX)
ASX:IBX
IBX Stock Chart & Stats
Day’s Range― - ―
52-Week RangeAU$0.01 - AU$0.10
Previous CloseN/A
Volume347.18K
Average Volume (3M)449.79K
Market Cap
AU$2.82M
Enterprise ValueAU$5.58M
Total Cash (Recent Filing)AU$1.14M
Total Debt (Recent Filing)AU$18.55K
Price to Earnings (P/E)―
Beta-0.16
Next Earnings
Aug 28, 2025EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.05
Shares Outstanding201,341,420
10 Day Avg. Volume485,157
30 Day Avg. Volume449,785
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)1.20
Price to Cash Flow (P/CF)N/A
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
---
Imagion Biosystems Ltd. News
PremiumCompany Announcements
Imagion Biosystems Applies for New Securities Quotation on ASX
PremiumCompany Announcements
Imagion Biosystems Reveals Strategic Holdings AnalysisPremiumCompany Announcements
Imagion Biosystems Announces New Securities Quotation on ASX
PremiumCompany Announcements
Imagion Biosystems Issues Cleansing Prospectus for New Options
PremiumCompany Announcements
Imagion Biosystems Announces 2025 AGM Date and Director Nomination Deadline
PremiumCompany Announcements
Imagion Biosystems Unveils Breakthrough in Cancer Detection Imaging
PremiumCompany Announcements
Imagion Biosystems Releases 2024 Corporate Governance StatementPremiumCompany Announcements
Imagion Biosystems Releases 2024 Annual Report---
Options Prices
Currently, No data available
---
Ownership Overview
3.07% Insiders
―
Mutual Funds
― Other Institutional Investors
96.93% Public Companies and
Individual Investors
IBX FAQ
What was Imagion Biosystems Ltd.’s price range in the past 12 months?
Imagion Biosystems Ltd. lowest share price was AU$0.01 and its highest was AU$0.10 in the past 12 months.
What is Imagion Biosystems Ltd.’s market cap?
Imagion Biosystems Ltd.’s market cap is AU$2.82M.
When is Imagion Biosystems Ltd.’s upcoming earnings report date?
Imagion Biosystems Ltd.’s upcoming earnings report date is Aug 28, 2025 which is in 126 days.
How were Imagion Biosystems Ltd.’s earnings last quarter?
Imagion Biosystems Ltd. released its earnings results on Feb 28, 2025. The company reported -AU$0.003 earnings per share for the quarter, missing the consensus estimate of N/A by -AU$0.003.
Is Imagion Biosystems Ltd. overvalued?
According to Wall Street analysts Imagion Biosystems Ltd.’s price is currently Overvalued.
Does Imagion Biosystems Ltd. pay dividends?
Imagion Biosystems Ltd. does not currently pay dividends.
What is Imagion Biosystems Ltd.’s EPS estimate?
Imagion Biosystems Ltd.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Imagion Biosystems Ltd. have?
Imagion Biosystems Ltd. has 201,341,420 shares outstanding.
What happened to Imagion Biosystems Ltd.’s price movement after its last earnings report?
Imagion Biosystems Ltd. reported an EPS of -AU$0.003 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Imagion Biosystems Ltd.?
Currently, no hedge funds are holding shares in AU:IBX
---
Imagion Biosystems Ltd. Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Blogger Sentiment
Bearish
AU:IBX Sentiment 67%
Sector Average 70%
Sector Average 70%
Insider Transactions
Bought Shares
Worth AU$100.0K over
the Last 3 Months
the Last 3 Months
News Sentiment
Neutral
Bullish news 59%
Bearish news 100%
Bearish news 100%
Technicals
SMA
―
20 days / 200 days
Momentum
-81.08%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-38.87%
Trailing 12-Months
Company Description
Imagion Biosystems Ltd.
Imagion Biosystems Limited provides medical imaging technologies based on superparamagnetic relaxometry for cancer and disease detection, and monitoring therapy. It has activities in nanotechnology; biotechnology; cancer diagnostics; and superparamagnetic relaxometry. The company develops MagSense, which is in Phase I clinical trials for the treatment of HER2 breast cancers; and PrecisionMRX, an iron oxide nanoparticle to detect cancer. Imagion Biosystems Limited has a collaborative research program with Patrys Limited to use the combined technologies for enhancing brain tumor imaging and diagnosis; and a joint development agreement with Global Cancer Technology, Inc. to develop GCT's novel nanoscintillator technology for the treatment of breast cancer. The company was incorporated in 2016 and is based in San Diego, California.
---
Technical Analysis
Biotron Limited
―
Mesoblast Limited
―
PYC Therapeutics Limited
―
Resonance Health Ltd
―
---